Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Nov 5;114(19):4283-92.
doi: 10.1182/blood-2009-07-232454. Epub 2009 Aug 21.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

Ann M Leen  1 , Anne Christin, Gary D Myers, Hao Liu, Conrad R Cruz, Patrick J Hanley, Alana A Kennedy-Nasser, Kathryn S Leung, Adrian P Gee, Robert A Krance, Malcolm K Brenner, Helen E Heslop, Cliona M Rooney, Catherine M Bollard
Affiliations
Clinical Trial

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

Ann M Leen et al. Blood. .

Abstract

Viral infection or reactivation remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. We now show that infusions of single cytotoxic T lymphocyte (CTL) lines (5 x 10(6)-1.35 x 10(8) cells/m(2)) with specificity for 2 commonly detected viruses, Epstein-Barr virus (EBV) and adenovirus, can be safely administered to pediatric transplantation recipients receiving partially human leukocyte antigen-matched and haploidentical stem cell grafts (n = 13), without inducing graft-versus-host disease. The EBV-specific component of the CTLs expanded in vivo and persisted for more than 12 weeks, but the adenovirus-specific component only expanded in vivo in the presence of concomitant adenoviral infection. Nevertheless, adenovirus-specific T cells could be detected for at least 8 weeks in peripheral blood, even in CTL recipients without viral infection, provided the adenovirus-specific component of their circulating lymphocytes was first expanded by exposure to adenoviral antigens ex vivo. After infusion, none of these 13 high-risk recipients developed EBV-associated lymphoproliferative disease, while 2 of the subjects had resolution of their adenoviral disease. Hence, bispecific CTLs containing both EBV- and adenovirus-specific T cells can safely reconstitute an antigen responsive "memory" population of CTLs after human leukocyte antigen-mismatched stem cell transplantation and may provide antiviral activity. This trial was registered at www.clinicaltrials.gov as #NCT00590083.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunophenotype of bivirus-specific CTL lines generated for clinical use. Reactivity of CTL lines (n = 20) with antibodies against the T-cell surface antigens CD3, CD4, CD8, and CD56, the monocyte surface antigen CD14, and the B-cell surface antigen CD19. Lines made from haploidentical donors are represented by circles (n = 8), and those made from matched unrelated donors are represented by triangles (n = 12).
Figure 2
Figure 2
Virus-specific activity of CTL as determined by Cr release assay. 51Cr release at 4 hours after coincubation of CTL lines with autologous nontransduced EBV-LCL (EBV target), autologous EBV-LCL transduced with Ad5f35null vector, or recipient PHA blasts (allogeneic target). Lines made from haploidentical donors are shown in the top panel (n = 8) and those made from matched unrelated donors are shown in the bottom panel (n = 12). The data are mean percentage lysis (± SEM) of targets by all 20 CTL lines at E/T ratios of 40:1, 20:1, 10:1, and 5:1.
Figure 3
Figure 3
Virus-specific activity of CTL as determined by IFN-γ ELIspot assay. T-cell specificity and cytokine production were assessed using the IFN-γ ELIspot assay by direct stimulation with hexon pepmix (adenovirus), penton pepmix (adenovirus), irradiated EBV-LCL at an E/T ratio of 1:1 (EBV), and an irrelevant pepmix (control). Results are presented as SFCs/105 CTLs. Lines made from haploidentical donors are represented by circles (n = 8), and those made from matched unrelated donors are represented by triangles (n = 12).
Figure 4
Figure 4
In vivo expansion and clinical benefits of EBV-specific T cells. (A) Frequencies of peripheral blood T cells responding to EBV-LCL by IFN-γ secretion before and after CTL infusion in 12 patients. Individual haploidentical recipients (n = 5) are represented by circles, and MUD recipients are represented by triangles (n = 7). Mean values are represented by lines: solid for haploidentical transplant recipients and dashed for MUDs. (B) Increase in the mean frequency of EBV-LCL-responsive peripheral blood T cells in patients 1, 2, and 3 is related to a decrease in EBV-DNA levels.
Figure 5
Figure 5
Effects of adenovirus-specific CTL in vivo. (A) ELIspot analysis of the frequency of peripheral blood T cells responding to irradiated Ad5f35-infected donor PBMCs by IFN-γ secretion before and after CTL infusion in patients without (n = 9; left panel) and with (n = 2; right panel) adenovirus infection at the time of receiving CTL. (B) Imaging studies are shown before and after CTL in a patient (patient 2) with adenovirus pneumonia who had a complete clinical response after T-cell infusion. A chest CT scan and chest radiograph demonstrate bilateral interstitial infiltrates. The follow-up chest radiograph 2 weeks after CTL infusion is reported as normal (C). Marked increase in adenovirus-specific T-cell precursor frequency in patient 2, and marked decrease in adenoviral load in stool from patient 10 after CTL infusion and clearance of virus coincident with a transient increase in adenovirus-specific T cells.
Figure 6
Figure 6
Amplification of adenovirus-specific T cells in vitro. (A) PBMCs from a haploidentical transplant recipient without adenovirus infection were stimulated in vitro with adenovirus antigens to amplify the frequency of adenovirus-reactive T cells and reanalyzed 9 days later by IFN-γ ELIspot. (B) Amplification of adenovirus-specific T cells from a MUD recipient without infection showing an increase in the adenovirus-specific T-cell precursor frequency using IFN-γ ELIspot.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100(5):1619–1627. - PubMed
    1. Chakrabarti S, MacKinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357–4363. - PubMed
    1. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008;143(2):169–179. - PMC - PubMed
    1. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–555. - PubMed
    1. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–1044. - PubMed

Publication types

MeSH terms

Associated data